Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

The Company encourages use of the webcast due to potential extended wait times to access the conference call via dial-in. The webcast of the conference call will be available in the Investor Relations ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

As the S&P 500 hovers near record highs and treasury yields drop following retail sales data, investors are keeping a close eye on the broader U.S. market trends. Penny stocks, often associated with ...

European shares were mostly higher today. The eurozone's STOXX 600 rose 1.01%, Germany's DAX 40 rose 1.77% and France's CAC ...

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 0.2% on Thursday. Following the ...

The New York Stock Exchange is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update?for market insights before trading begins.  Kristen ...

TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...

Edesa Biotech (EDSA) announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and ...